Welcome to the New Mexico Chapter of the American College of Cardiology
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!.
For more information and to register, please visit: 
Latest in Cardiology from ACC.org
- FASTR: Reprieve System Safely Accelerates Decongestion in Acute HFThe Reprieve System, a three-part approach to diuretic therapy, safely produced significantly faster decongestion in patients with acute heart failure (HF) compared with optimal diuretic therapy (ODT), according to results of the FASTR trial published May 4 in JACC: Heart Failure.
- JACC Journals Science at ESC Heart Failure Congress 2026Findings from several studies presented at ESC Heart Failure Congress 2026 in Barcelona, Spain, were simultaneously published in JACC and JACC: Heart Failure, covering topics like arrhythmic burden in cardiac amyloidosis (CA), stroke and bleeding risk in CA...
- Cardiopulmonary Exercise Testing in Congenital Heart Disease: From Pediatric Through AdultCardiopulmonary exercise testing (CPET) is a noninvasive tool providing information on the interactions between the cardiovascular (CV), pulmonary, and skeletal muscle systems as well as total body metabolic response to exercise.
- ACCEL Lite: Inflammation in CVD: A 2025 ACC Scientific StatementInflammation has emerged as a critical contributor to the pathogenesis and clinical outcomes of cardiovascular disease (CVD), with growing evidence highlighting the prognostic relevance of residual inflammatory risk.
- Study Provides Evidence For Incorporating CMR and NT-proBNP Into HCM Risk EvaluationResults from a prospective study using data from the National Heart, Lung, and Blood Institute’s Hypertrophic Cardiomyopathy (HCM) Registry provide important evidence in support of incorporating cardiac magnetic resonance (CMR) imaging and NT-proBNP into the evaluation of risk in patients with HCM.